Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Carocare Wellness vs Revel RX

Carocare Wellness
Graded #378

Lower grade

vs+19.199999999999996
Revel RX
Graded #47

Higher grade

The verdict

Revel RX takes it — 77.3/100 to 58.1/100.

Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRevel RX +37
59
96
Dose & formulationRevel RX +8
64
72
Clinical oversightRevel RX +15
69
84
Labs & monitoringEven
53
53
FulfillmentRevel RX +21
60
81
Contract termsRevel RX +35
20
55
Carocare Wellness · left barRevel RX · right bar

The numbers

MetricCarocare WellnessRevel RX
WeighScore58.1/10077.3/100
GradeCC+
Scorecard rank#378#47
Semaglutide$170/mo (compounded)$89/mo (all doses, compounded)
Tirzepatide$200/mo (compounded)$155/mo (all doses, compounded)
Coverage1 stateCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Carocare Wellness

Graded #378 · C

Strengths

  • Real, named local clinic in Houston with hands-on provider support, in-person visits and Google-reviewed patient experiences
  • Low entry pricing — semaglutide from $170 and tirzepatide from $200 in month 1, with 3-month bundles ($500 / $600) that cut the effective monthly cost
  • Packages include ongoing provider support, supplies and delivery
  • Also offers IV hydration and NAD+ if you want broader wellness services in one place

Where it loses points

  • Houston/Texas only — no nationwide telehealth, so it is not an option outside the local area
  • Dose-escalating pricing climbs steeply (semaglutide reaches $330 by month 5; tirzepatide $425 by month 6)
  • Compounding pharmacy is not named, and there is no LegitScript or published clinical-oversight detail
  • Small single-location operation with no patient portal — booking and support run through Calendly and direct contact
  • Compounded semaglutide and tirzepatide only — no brand-name or oral options
Revel RX

Graded #47 · C+

Strengths

  • Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
  • LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
  • Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
  • Free overnight cold shipping included; no hidden fees or dose-based price increases
  • Clinical review by MD Integrations, an independent medical group, before any prescription is issued

Where it loses points

  • States served are not publicly listed; eligible states requires completing intake to confirm coverage
  • No labs, coaching, or ongoing health support disclosed in any public materials
  • Compounded medications are not FDA-approved (site discloses this)
  • Newer brand with limited public patient reviews or Trustpilot rating
  • Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard